Anixa Biosciences Inc: Form 10-Q for the period ended Jan 31, 2023
Filed with the SEC on Mar 17, 2023 and accepted by EDGAR at Mar 16, 2023, 21:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-11-01 to 2023-01-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-11-01 to 2023-01-31 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-11-01 to 2023-01-31 | −$2.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-11-01 to 2023-01-31 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-11-01 to 2023-01-31 | 30,921 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-11-01 to 2023-01-31 | −$2.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-01-31 | $9.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-01-31 | $28.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-01-31 | $28.3m | us-gaap:Assets |
| Current liabilities | At period end2023-01-31 | $1.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-01-31 | $1.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-01-31 | $27.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-007994. Last ingested by Listed: Nov 2, 2026, 08:56 ET. Listed shows no prices and gives no investment advice.